Vallon Pharma dives as ADHD treatment fails to meet study main goal

GRI Bio

21/03/2022 12:09

** Shares of biopharmaceutical company  VLON.O  fall ~77% to
$1.70 premarket; set for worst day on record, if losses hold
    ** Co's experimental treatment for attention deficit
hyperactivity disorder (ADHD) failed to meet main goal of a
late-stage study (https://refini.tv/36fFcRk)
    ** The drug, ADAIR, failed to show significant reduction in
'Drug Liking' in recreational drug users when compared to
d-amphetamine sulfate and placebo in study
    ** D-amphetamine sulfate is a central nervous system
stimulant that is prescribed for the treatment of attention
deficit hyperactivity disorder and narcolepsy
    ** ADAIR met study's secondary goals with statistical
significance - VLON
    ** Co will determine next steps for the development program,
including plans to request a formal meeting with the FDA in the
coming months and the potential for an additional study
    ** Stock rose 24.41% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))